Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Therapeutic agents in soy can treat colon cancer, says study

A study conducted by Children's Hospital & Research Center Oakland scientists identifies a new class of therapeutic agents found naturally in soy that can prevent and possibly treat colon cancer, the third most deadly form of cancer. Sphingadienes (SDs) are natural lipid molecules found in soy that research shows may be the key to fighting colon cancer.

24 Nov 2009

Scientists use exome sequencing method to discover the cause of mendelian disorder

For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder.

20 Nov 2009

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.

17 Nov 2009

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm Corporation today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

16 Nov 2009

New updated education course from PARI Respiratory Equipment

Today, PARI Respiratory Equipment launched a newly updated continuing education class, Managing Respiratory Patients Through Efficient Aerosol Delivery, rounding out their free learning program with seven classes for respiratory therapists, nurses, case managers, and pharmacists.

13 Nov 2009

Vertex Pharmaceuticals announces exchange agreement with holders of its 4.75% Convertible Senior Subordinated Notes

Vertex Pharmaceuticals Incorporated announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued interest for approximately 4.8 million shares of the Company’s common stock, which is approximately 140,000 shares more than the number of shares into which the notes were convertible under their original terms.

11 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

Third quarter 2009 financial results announced by Aradigm

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2009 and recent highlights.

5 Nov 2009

Can American ginseng relieve health problems?

With the current outbreak of influenza-like illnesses, many people are trying to boost their immune systems with supplements. Ginseng is often a key ingredient, but its therapeutic use may extend far beyond that. Researchers are now investigating whether ginseng can help relieve health problems ranging from diabetes to depression to erectile dysfunction.

5 Nov 2009

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Scientists in Belgium have successfully differentiated human embryonic stem cells (hESC) into major cell types of lung epithelial tissue using a convenient air-liquid interface.

5 Nov 2009

Patient enrollment in three late-stage clinical trials completed

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.

5 Nov 2009

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.

2 Nov 2009

Pulmatrix raises $30.2 million through Series B financing

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.

2 Nov 2009

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.

2 Nov 2009

Bacteria use a well-studied communication system to resist antibiotics

Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.

1 Nov 2009

University of Iowa receives a $26.4M gift commitment from the Pappajohns

University of Iowa President Sally Mason announced today a $26.4 million gift commitment from longtime UI benefactors John and Mary Pappajohn of Des Moines -- the largest single gift commitment ever for the UI from individual Iowa donors -- and said it will provide the university's new interdisciplinary Institute for Biomedical Discovery with "the catalyst it needs to reach its full potential."

30 Oct 2009

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical industry.

29 Oct 2009

GeneGo to launch new web site with high quality pathway content

GeneGo, Inc., the leading systems biology tools company, announced today that they will be launching a new web site with FREE high quality pathway content. On www.genego.com, anyone can now search for genes, proteins, compounds, processes and diseases and access high quality manually curated pathway maps for human, mouse and rat signaling and metabolism.

29 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

MMRF raises over $1.8 million at its 13th annual Fall Gala

The Multiple Myeloma Research Foundation (MMRF) raised over $1.8 million at its 13th annual Fall Gala held on Saturday evening in Greenwich, Conn. Funds raised at this premier fundraising event, attended by more than 1,000 guests, will support the MMRF’s efforts to accelerate the development of the next generation of treatments for patients with multiple myeloma, a rare and incurable blood cancer, and to find a cure for the disease.

28 Oct 2009

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Therapeutic agents in soy can treat colon cancer, says study

Scientists use exome sequencing method to discover the cause of mendelian disorder

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

New updated education course from PARI Respiratory Equipment

Vertex Pharmaceuticals announces exchange agreement with holders of its 4.75% Convertible Senior Subordinated Notes

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Third quarter 2009 financial results announced by Aradigm

Can American ginseng relieve health problems?

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Patient enrollment in three late-stage clinical trials completed

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix raises $30.2 million through Series B financing

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Bacteria use a well-studied communication system to resist antibiotics

University of Iowa receives a $26.4M gift commitment from the Pappajohns

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

GeneGo to launch new web site with high quality pathway content

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

MMRF raises over $1.8 million at its 13th annual Fall Gala

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in